

Product Data Sheet

IFN-alpha 4/IFNA4 Protein, Human (HEK293, His)

Cat. No.:	HY-P72615
Synonyms:	Interferon alpha-4; Interferon alpha-4B; Interferon alpha-76; Interferon alpha-M1; IFNA4
Species:	Human
Source:	HEK293
Accession:	P05014 (C24-D189)
Gene ID:	3441
Molecular Weight:	Approximately 20 kDa

DDODEDTIES	
PROPERTIES AA Sequence	CDLPQTHSLG NRRALILLAQ MGRISHFSCL KDRHDFGFPE EEFDGHQFQK AQAISVLHEM IQQTFNLFST EDSSAAWEQS
	EEFDGHQFQK AQAISVLHEM IQQTFNLFST EDSSAAWEQS LLEKFSTELY QQLNDLEACV IQEVGVEETP LMNEDSILAV RKYFQRITLY LTEKKYSPCA WEVVRAEIMR SLSFSTNLQK RLRRKD
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	IFN-alpha 4 (IFNA4; IFN-α4), belongs to the alpha/beta interferon (IFN) family, is produced by the macrophages with antiviral activities. Interferon (IFN) is originally identified as a substance 'interfering' with viral replication in vitro. IFN-α/β and related molecules are classified as type I IFNs, as for the other two types of type II IFN (IFN-γ) and type III IFNs (IFN-λ), respectively ^[1] .
	Interferon alpha (IFNa) shows significant biological activity in various cancers, paticularly haematological malignancies such as hairy cell leukaemia and chronic myelogenous leukaemia ^[2] . IFN-alpha 4 is the subtypes dominates in IFN-alpha, whose the response with IFNA5, IFNA7, and IFNA14 accounting for up to

85% of the subtypes expressed by Peripheral blood mononuclear cells (PBMCs)^[3]. IFN-alpha 4 is promoted by interferon (IFN) regulatory factors (IRFs), especially IRF-1 and IRF-7^{[5][6]}. And it exhibits function by inhibiting virus RNA replication and enhances human natural killer cytotoxicity against virus^{[4][7]}. As for a wildly use of IFN in animal model, the sequence of amino acids in IFNA4 protein of human is very different from mouse (57.07%) and rat (57.98), respectively.

REFERENCES

[1]. Zhang SY, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev. 2008 Dec;226:29-40.

[2]. Raj NB, et al. Identification of a novel virus-responsive sequence in the promoter of murine interferon-alpha genes. J Biol Chem. 1991 Jun 15;266(17):11360-5.

[3]. Li Y, et al. Expression Pattern of Individual IFNA Subtypes in Chronic HIV Infection. J Interferon Cytokine Res. 2017 Dec;37(12):541-549.

[4]. Verhagen A, et al. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Nat Immun Cell Growth Regul. 1990;9(5):325-33.

[5]. Au WC, et al. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11657-61.

[6]. Lin R, et al. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol Cell Biol. 2000 Sep;20(17):6342-53.

[7]. Xiao CX, et al. Exome sequencing identifies novel compound heterozygous IFNA4 and IFNA10 mutations as a cause of impaired function in Crohn's disease patients. Sci Rep. 2015 May 22;5:10514.

Caution: Product has not been fully validated for medical applications. For research use only.